Authors: Banerjee S.; Dick A.D.

Source: Expert Opinion on Investigational Drugs, Volume 12, Number 1, 1 January 2003 , pp. 29-37(9)

Publisher: Informa Healthcare

Abstract:

At present, given the high initial success rate of corneal transplantation (although late survival is poor), immunosuppression is often reserved for ‘high-risk’ patients. Despite immune privilege, corneal graft rejection remains the leading cause of corneal allograft failure. Interpreting the limited and also restricted design of most trials, immunosuppressive therapy has not enjoyed the success seen in solid organ grafts. This review discusses the limited data available whilst proposing newer therapies that have developed as a result of our increased understanding of the immunobiology of corneal graft rejection.

Keywords: corneal transplantation; corticosteroids; cyclosporin A; immunosuppressants; mAb therapies; mycophenolate mofetil; tacrolimus

Document Type: Review article

Publication date: 2003-01-01

More about this publication?

• Editorial Board
• Information for Authors
• Subscribe to this Title
• Terms & Conditions
• ingentaconnect is not responsible for the content or availability of external websites

Related content

• In this: publication
• By this: publisher
• In this Subject: Pharmacology
• By this author: Banerjee S. ;  Dick A.D.

Website © Publishing Technology. Article copyright remains with the publisher, society or author(s) as specified within the article.

• Terms and conditions
• Privacy policy
• Information for advertisers